Medical device packaging testing is not a single test but a documented sequence of design evaluation and process validation. ASTM F2097 provides a compendium of test methods for primary flexible packages, while ISO 11607-2 specifies requirements for validating forming, sealing and assembly processes [1][3]. The two documents serve different functions: F2097 helps a manufacturer select applicable methods after product characterization and sterilization methodology are defined, whereas ISO 11607-2 establishes how to demonstrate that the packaging process itself is controlled [1][3]. Neither standard supplies acceptability criteria. Those limits must be determined jointly by the package producer and the medical products manufacturer [1]. A practical program therefore begins with product characterization, moves through method selection, and ends with installation, operational and performance qualification of the packaging line.
Design Evaluation Begins With Product Characterization
ASTM F2097 describes multiple categories for evaluating flexible medical packages and packaging materials, including safety, barrier, material and package performance attributes, package integrity, visibility and appearance, processing, printed ink, distribution simulation, and conditioning [1]. The guide does not prescribe a universal test battery. Specific individual test methods must be selected based on the pertinent characteristics of the product to be packaged and the purpose for testing, whether research and development or compliance [1]. Not all test methods will be applicable to every package configuration.
Product characterization is a prerequisite for that selection. The historical F2097-23 text states that characterization shall include mass or weight, geometry such as length, width, height and shape, and product composition [2]. The current F2097-25 retains the same design and evaluation intent while noting that once the product has been characterized and the sterilization methodology has been defined, numerous sets of requirements exist for any specific package [1]. The guide explicitly does not assess the product to be packaged or the sterilization method to be used [1]. Those inputs must come from the device manufacturer before packaging evaluation can proceed.
Process Validation Under ISO 11607-2
ISO 11607-2:2019 specifies requirements for the development and validation of processes for packaging medical devices that are terminally sterilized. These processes include forming, sealing and assembly of preformed sterile barrier systems, sterile barrier systems and packaging systems [3]. The standard applies to industry, to health care facilities, and to wherever medical devices are packaged and sterilized [3]. It does not cover all requirements for packaging medical devices that are manufactured aseptically, and additional requirements can be necessary for drug/device combinations [3].
A UL white paper on validating medical device packaging describes the qualification sequence as installation qualification, operational qualification, and performance qualification [7]. Installation qualification includes assessment of operator training and instructions for routine equipment cleaning and maintenance, while operational qualification evaluates the parameters for forming, sealing and assembly [7]. Performance qualification compares results with the initial qualification; consistent results are usually sufficient to verify continued validity, while deviations may signal the need for further evaluation [7]. The white paper also notes that software validation may be required where installed equipment is controlled or managed by software [7].
Hypothetical Evaluation Sequence for a Pouch-Sealed Device
Consider a hypothetical single-use catheter packaged in a preformed flexible pouch with a porous Tyvek-style header. The manufacturer would first document mass, geometry and composition of the catheter, then define the sterilization method [2]. Because the header is porous, dye penetration per ASTM F1929-23 would be a candidate integrity method, while ASTM F3039-23 would apply to a nonporous configuration [5]. Seal strength would be evaluated per ASTM F88/F88M-23 [5]. Accelerated aging conditions would be selected under ASTM F1980, with attention to staying within the material's operational capability [1]. Process validation would then follow ISO 11607-2, covering pouch formation, sealing and assembly [3]. This sequence is a suggested illustration, not a required protocol; acceptability criteria would still need to be set jointly by the package producer and device manufacturer [1].
Integrity and Seal Strength Methods
Package integrity and seal strength are evaluated through distinct test methods. Westpak, a commercial testing laboratory, lists gross leak bubble testing, dye penetration testing, seal strength peel testing, and burst tests among its validated medical device package testing procedures [4]. The company states that medical device package validation incorporates package performance testing, accelerated aging, and sterile integrity testing following the guidelines of ISO 11607-1 and ISO 11607-2 [4]. Westpak also lists distribution testing, temperature and humidity testing, accelerated aging, and real-time aging as available procedures [4].
FDA recognition records identify several consensus standards for these methods. ASTM F1929-23 covers detecting seal leaks in porous medical packaging by dye penetration, while ASTM F3039-23 covers detecting leaks in nonporous packaging or flexible barrier materials by dye penetration [5]. ASTM F88/F88M-23 addresses seal strength of flexible barrier materials [5]. ASTM F1886/F1886M-16 covers determining integrity of seals for flexible packaging by visual inspection [8]. The distinction between porous and nonporous methods matters because a dye penetration approach suitable for one material class may not apply to the other.
Aging, Distribution and Shelf-Life Evidence
Accelerated aging is frequently used in the early development of medical packaging, and ASTM F1980 provides guidance on selecting time and temperature conditions [1]. The F2097 guide notes that failures often occur due to the selection of aging conditions outside of the material's operational capability [1]. Real-time aging remains a separate evidence stream. Westpak lists both accelerated aging and real-time aging among its testing procedures [4]. The UL white paper states that manufacturers must be able to validate claims regarding expected shelf-life, meaning the period during which seal strength and packaging integrity can be assured [7].
Distribution simulation connects laboratory aging to real-world handling. ASTM F2825-18 covers climatic stressing of packaging systems for single parcel delivery [8]. The UL white paper describes transport safety evaluation as the final aspect of validation, encompassing evaluation of the packaging system's performance during transportation, distribution and storage [7]. Specific standardized test methods for demonstrating that the sterile barrier system remains compliant with ISO 11607-1 after shipment are mentioned in Annex B of the standard [7]. The exact test sequence depends on the distribution environment, which the manufacturer must define.
Regulatory Recognition and Voluntary Use
Many of the standards included in ASTM F2097 are consensus standards recognized by the United States Food and Drug Administration [1]. Selection and use of an FDA recognized consensus standard is voluntary and the sole responsibility of the user in determining its applicability [1]. FDA recognition records show ISO 11607-1 and ISO 11607-2, both second edition 2019-02 including Amendment 1:2023, as complete standards under the Sterility specialty task group [5]. ASTM F2097-20 appears in the FDA recognition database with a recognition date of December 21, 2020 [5].
The voluntary nature of consensus standards does not remove the need for documented rationale. ASTM F2097 states that all cited categories must be considered for applicability [2]. The intent is to evaluate all cited categories and select those that are applicable [1]. A manufacturer cannot simply omit a category without justification. The guide provides an avenue for assessing requirements and choosing test methods for both evaluating the package design and monitoring package compliance [1]. That dual purpose means the same method may serve design verification and ongoing production monitoring, but the acceptance limits may differ.
Sources & references
- F2097 Standard Guide for Design and Evaluation of Primary Flexible Packaging for Medical Products · store.astm.org
- F2097 Standard Guide for Design and Evaluation of Primary Flexible Packaging for Medical Products · store.astm.org
- ISO 11607-2:2019 - Packaging for terminally sterilized medical devices — Part 2: Validation requirements for forming, sealing and assembly processes · www.iso.org
- Medical Device Testing - Package Validation Services | Westpak · westpak.com
- Recognized Consensus Standards: Medical Devices · www.accessdata.fda.gov
- Recognized Consensus Standards: Medical Devices · www.accessdata.fda.gov
- VALIDATING MEDICAL DEVICE PACKAGING · code-authorities.ul.com
- Recognized Consensus Standards: Medical Devices · www.accessdata.fda.gov